[{"id":"918344be-dd4e-4358-a794-c4dce84f54ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT06171282","created_at":"2023-12-14T17:18:21.443Z","updated_at":"2024-07-02T16:35:26.226Z","phase":"Phase 1","brief_title":"A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors","source_id_and_acronym":"NCT06171282","lead_sponsor":"Shanghai Yunying Medical Technology","biomarkers":" IFNG • IL6 • TNFA • IL2 • IL10","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e R130"],"overall_status":"Recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 07/12/2023","start_date":" 07/12/2023","primary_txt":" Primary completion: 07/12/2025","primary_completion_date":" 07/12/2025","study_txt":" Completion: 07/12/2026","study_completion_date":" 07/12/2026","last_update_posted":"2023-12-14"},{"id":"befd90fe-42a7-4ced-ae3e-ff90b2e619f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05961111","created_at":"2023-07-27T18:09:03.326Z","updated_at":"2024-07-02T16:35:41.843Z","phase":"Phase 1","brief_title":"A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors","source_id_and_acronym":"NCT05961111","lead_sponsor":"Shanghai Yunying Medical Technology","biomarkers":" IL6 • CXCL8 • IL2 • IL10 • IL4","pipe":"","alterations":" ","tags":["IL6 • CXCL8 • IL2 • IL10 • IL4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e R130"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/24/2023","start_date":" 06/24/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2023-07-27"},{"id":"69d3f93b-bc65-4950-b96a-cb0c18e1241f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05886075","created_at":"2023-06-02T14:06:05.908Z","updated_at":"2024-07-02T16:35:46.614Z","phase":"Phase 1","brief_title":"A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors","source_id_and_acronym":"NCT05886075","lead_sponsor":"Shanghai Yunying Medical Technology","biomarkers":" IL6 • CXCL8 • IL2 • IL10 • IL4","pipe":"","alterations":" ","tags":["IL6 • CXCL8 • IL2 • IL10 • IL4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e R130"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 03/30/2023","start_date":" 03/30/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2023-06-02"},{"id":"049ebbe4-3822-4f58-b863-4709ccc7c019","acronym":"","url":"https://clinicaltrials.gov/study/NCT05860374","created_at":"2023-05-16T17:06:32.908Z","updated_at":"2024-07-02T16:35:47.882Z","phase":"Phase 1","brief_title":"A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors","source_id_and_acronym":"NCT05860374","lead_sponsor":"Shanghai Yunying Medical Technology","biomarkers":" IL6 • CXCL8 • IL2 • IL10 • IL4","pipe":"","alterations":" ","tags":["IL6 • CXCL8 • IL2 • IL10 • IL4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e R130"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/02/2023","start_date":" 03/02/2023","primary_txt":" Primary completion: 03/02/2025","primary_completion_date":" 03/02/2025","study_txt":" Completion: 03/02/2026","study_completion_date":" 03/02/2026","last_update_posted":"2023-05-16"},{"id":"f8d0c3ae-87fa-414c-9eb9-d863a7bbf093","acronym":"","url":"https://clinicaltrials.gov/study/NCT05851456","created_at":"2023-05-09T14:04:41.504Z","updated_at":"2024-07-02T16:35:48.676Z","phase":"Phase 1","brief_title":"A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Bone and Soft Tissue Tumors","source_id_and_acronym":"NCT05851456","lead_sponsor":"Shanghai Yunying Medical Technology","biomarkers":" IL6 • CXCL8 • IL2 • IL10 • IL4","pipe":"","alterations":" ","tags":["IL6 • CXCL8 • IL2 • IL10 • IL4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e R130"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 04/10/2023","start_date":" 04/10/2023","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2023-05-09"},{"id":"4508f571-d999-49fb-aef8-b58a7b46701d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05830240","created_at":"2023-04-26T14:04:49.427Z","updated_at":"2024-07-02T16:35:49.548Z","phase":"Phase 1","brief_title":"A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Relapsed/Refractory Head and Neck Cancer","source_id_and_acronym":"NCT05830240","lead_sponsor":"Shanghai Yunying Medical Technology","biomarkers":" IL6 • CXCL8 • IL2 • IL10 • IL4","pipe":"","alterations":" ","tags":["IL6 • CXCL8 • IL2 • IL10 • IL4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e R130"],"overall_status":"Recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 03/27/2023","start_date":" 03/27/2023","primary_txt":" Primary completion: 03/27/2025","primary_completion_date":" 03/27/2025","study_txt":" Completion: 03/27/2026","study_completion_date":" 03/27/2026","last_update_posted":"2023-04-26"}]